Deciphering the role of mTORC1 in PTEN-deficient prostate cancer has been largely assessed through a series of studies using sirolimus (rapamycin) and its analogues (rapalogs), which potently inhibit mTORC1, with minimal effect on mTORC2, unless under prolonged exposure [221,222]. This evidence concerns the gene PTEN and prostate carcinoma.